Currently Viewing:
Currently Reading
FDA Approves Gene Therapy With $2.1M Price Tag for Spinal Muscular Atrophy in Pediatric Patients
May 24, 2019 – Jaime Rosenberg
Evobrutinib Reduced Signs of Active Inflammation in Patients with Multiple Sclerosis
May 24, 2019 – Wallace Stephens
AJMC® in the Press, May 24, 2019
May 24, 2019 – AJMC Staff
5 Key Policy Issues for Employers and Mental Health
May 24, 2019 – Mary Caffrey
What We're Reading: Bipartisan Healthcare Package; Colorado Caps Insulin Prices; FDA Authorizes Zika Diagnostic Test
May 24, 2019 – AJMC Staff
This Week in Managed Care: May 24, 2019
May 24, 2019
Suspension of a Rural Syringe Service Program Increased Risks of HIV and HCV Acquisition
May 23, 2019 – Wallace Stephens
How Cells Slow Cancer That Has Reached Bone
May 23, 2019 – Laura Joszt
LifeScan Finds Partner to Move Into CGM Market
May 23, 2019 – Mary Caffrey

Sanofi Announces Tentative FDA Approval for Insulin Lispro

AJMC Staff
The rapid-acting insulin received tentative approval based on its similarity to Eli Lilly's Humalog.
Sanofi announced Friday that FDA has granted tentative approval for its rapid-acting insulin lispro injection 100 units/mL, which will have the trade name Admelog if the drug becomes available.

The tentative approval is based on physicochemical, nonclinical and clinical similarity to Eli Lilly’s Humalog. The European Commission approved the product in July under the trade name Insulin lispro Sanofi.

Rapid-acting insulin is taken at mealtime. FDA tentative approval is based on a development program involving adults with type 1 and type 2 diabetes. Tentative approval means the data in the marketing application were complete to qualify for approval, but that there are unresolved patent issues.

"Sanofi is committed to broadening our portfolio of products to help people living with diabetes manage their blood sugar," Stefan Oelrich, senior vice president and head, Global Diabetes Franchise, Sanofi, said in a statement. "With this tentative approval, we are now one step closer to offering Admelog as an option for those who use rapid-acting insulin."

Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up